Johnson & Johnson stopped the Covid-19 vaccine trial due to unexplained disease in patients.
One of the most high-profile efforts to contain the global pandemic was delayed, Johnson & Johnson said, on Monday in a participant who temporarily halted his Covid-19 vaccine trial due to an unexplained illness.
The Johnson & Johnson company said in a statement that.
The participant’s disease review and evaluation is being carried out by an independent data and safety monitoring board, as well as the company’s pathologists and safety practitioners,
Johnson & Johnson, which reported the quarterly financial results to report on Tuesday morning, has said that such stagnation is uniquely insignificant tests, which may involve thousands.
And the report also notes that the “study stagnation” in giving vaccine candidate supplements was different from the “regulatory hold” required by health officials. The present case is a break.
However, the move to Jammu and Kashmir is similar to that by AstraZeneca plc. In September, AstraZeneca stopped late-stage trials of his experimental coronavirus vaccine developed with the University of Oxford in a UK study participant due to an unexplained disease.
While tests have resumed in the UK, Brazil, South Africa, and India, testing in the US is still pending a regulatory review.
Dr. William Schaffner said
Dr. William Schaffner, a professor of infectious diseases at Vanderbilt University School of Medicine, said by email that “everyone is on alert with what happened to AstraZeneca,” adding that it could take a week to gather information.
“This will be a severe adverse event. If it were a significant illness such as prostate cancer, uncontrolled diabetes, or a heart attack – they wouldn’t be able to stop it for any of those reasons. It is likely to be a neurological event.
Last month, Johnson & Johnson stated that its experimental covid-19 vaccine produced a robust immune response against the novel coronavirus in an early-to-mid-stage clinical trial, At the end of this year or early 2021, the results of the tests that the company expected were closed, the final 60,000 person trials.